Trial · NCT03200717
Results by group106
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 106
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | Cycle 4 Day 1 | 1.8 | Standard Deviation 4.22 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 4 Day 1 | 0.2 | Standard Deviation 3.24 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 5 Day 1 | 0.1 | Standard Deviation 3.13 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | Cycle 5 Day 1 | 2.0 | Standard Deviation 2.35 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 5 Day 1 | 0.4 | Standard Deviation 3.06 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 6 Day 1 | -0.3 | Standard Deviation 5.68 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | Cycle 6 Day 1 | 2.7 | Standard Deviation 3.27 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 6 Day 1 | 0.3 | Standard Deviation 5.36 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 7 Day 1 | -0.1 | Standard Deviation 3.47 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | Cycle 7 Day 1 | 2.5 | Standard Deviation 3.73 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 7 Day 1 | 0.4 | Standard Deviation 3.63 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 9 Day 1 | -0.1 | Standard Deviation 4.22 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 9 Day 1 | -0.1 | Standard Deviation 4.22 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 11 Day 1 | 0.7 | Standard Deviation 3.30 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | Cycle 11 Day 1 | 0.0 | Standard Deviation NA | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 11 Day 1 | 0.6 | Standard Deviation 3.20 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 13 Day 1 | 1.4 | Standard Deviation 2.12 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 13 Day 1 | 1.4 | Standard Deviation 2.12 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 16 Day 1 | 0.6 | Standard Deviation 1.59 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 16 Day 1 | 0.6 | Standard Deviation 1.59 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03200717/results?page=2